The Centers for Medicare & Medicaid Services today proposed Medicare cover chimeric antigen receptor T-cell (CAR T) therapies approved by the Food and Drug Administration when they are prescribed by the treating oncologist and performed in a hospital meeting certain criteria. The proposed “coverage with evidence development” decision would require eligible patients receiving CAR T to be enrolled in a national registry or CMS-approved clinical study, and followed for at least two years to examine patient outcomes, clinical characteristics and health-related quality of life. The FDA in 2017 approved two CAR T-cell therapies for treating certain leukemias and lymphomas, which require safety monitoring through an FDA risk evaluation and mitigation strategy. The treatments are individually made by modifying the patient’s own T-cells, a type of white blood cell. CMS will accept comments on the proposed coverage decision through March 17. 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services yesterday released a fact sheet for state and local governments seeking Medicare, Medicaid or Children’s…
Headline
Over 1,750 Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs…
Headline
The Government Accountability Office today named three new members to the Medicare Payment Advisory Commission through April 2023. They are: Wayne…
Headline
More than half of U.S. adults aged 70 and older have experienced a disruption in their medical care during the first month of social distancing for COVID-19,…
Headline
The AHA and other national hospital organizations today urged the Department of Health and Human Services and Centers for Medicare & Medicaid Services to…
Headline
The Medicare Hospital Insurance Trust Fund will have sufficient funds to pay full benefits until 2026, according to the latest annual report from the…